Insilico Medicine expands synthetic lethality portfolio with t...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
NEW YORK, May 6, 2022 /PRNewswire-AsiaNet/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A...
Authors: LATEST ASIANET NEWS RELEASES